--- title: "Telomir Pharmaceuticals (TELO) news: offering" url: "https://aibio.space/companies/telomir-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TELO offering news: Telomir Pharmaceuticals sells about $5.6 million of common stock in PIPE. Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), United States." --- TELO Telomir Pharmaceuticals, Inc. NASDAQ · United States # Telomir Pharmaceuticals (TELO) news TELO offering news Financings · 2026-10-06 ## [Telomir Pharmaceuticals sells about $5.6 million of common stock in PIPE](https://aibio.space/news/telomir-pharmaceuticals-sells-about-5-6-million-common-stock-pipe/) Telomir sold 4,843,300 shares at $1.16 each, a 5% discount to its 10-day VWAP, in a PIPE with no warrants. Alexander Capital, L.P. was placement agent, and John Paul DeJoria put in an additional $1.0 million. ## Latest Telomir Pharmaceuticals news 1. 2026-04-24 Mergers [Telomir Pharmaceuticals completes acquisition of TELI Pharmaceuticals for 34,389,710 shares](https://aibio.space/news/telomir-pharmaceuticals-completes-acquisition-teli-pharmaceuticals-34/) Telomir acquired 100% of TELI on April 22, 2026 and now holds the global rights to Telomir-1. Bayshore Trust contributed $1 million at closing and entered an option to pay up to $4 million more if milestones are met. 2. 2025-05-21 Financings [Telomir Pharmaceuticals raises $3 million in private placement with largest shareholder's trust](https://aibio.space/news/telomir-pharmaceuticals-raises-3-million-private-placement-largest/) Telomir sold 1 million restricted shares at $3.00 each to The Bayshore Trust, an entity affiliated with its largest shareholder. The price is 18% above the $2.54 closing price on the day of signing, and an earlier insider purchase in December 2024 was made at $7.00 a share. ## Telomir Pharmaceuticals at a glance - **Ticker**: TELO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2025**: $754,323 ### Related companies - [Indivior Pharmaceuticals](https://aibio.space/companies/indivior-pharmaceuticals/) NASDAQ: INDV - [Collegium Pharmaceutical](https://aibio.space/companies/collegium-pharmaceutical/) NASDAQ: COLL - [Skinvisible](https://aibio.space/companies/skinvisible/) OTC: SKVI - [IDEAYA Biosciences](https://aibio.space/companies/ideaya-biosciences/) NASDAQ: IDYA - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) NASDAQ: ATYR - [BeyondSpring](https://aibio.space/companies/beyondspring/) NASDAQ: BYSI - [Genelux](https://aibio.space/companies/genelux/) NASDAQ: GNLX - [Liquidia](https://aibio.space/companies/liquidia/) NASDAQ: LQDA ### Also on NASDAQ - [Tvardi Therapeutics](https://aibio.space/companies/tvardi-therapeutics/) TVRD - [IN8bio](https://aibio.space/companies/in8bio/) INAB - [Pharvaris](https://aibio.space/companies/pharvaris-n-v/) PHVS - [bioAffinity Technologies](https://aibio.space/companies/bioaffinity-technologies/) BIAF - [ADARx Pharmaceuticals](https://aibio.space/companies/adarx-pharmaceuticals/) ADRX - [Aspire-Lakewood Holdings](https://aibio.space/companies/aspire-lakewood/) ASBP ## Telomir Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1971532/000149315226010625/) | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1971532/000149315226010625/) | | Net income (loss) | [-$10.4 million](https://www.sec.gov/Archives/edgar/data/1971532/000149315226010625/) | [-$16.5 million](https://www.sec.gov/Archives/edgar/data/1971532/000149315226010625/) | | Cash from operations | [-$3.7 million](https://www.sec.gov/Archives/edgar/data/1971532/000149315226010625/) | [-$5.1 million](https://www.sec.gov/Archives/edgar/data/1971532/000149315226010625/) | | Cash and equivalents | | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1971532/000164117225023970/) | Latest balance sheet, Jun 30, 2025 (10-Q): cash and equivalents $754,323. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Telomir Pharmaceuticals Has Telomir Pharmaceuticals raised money recently? Our latest story on this, dated Oct 6, 2026: "Telomir Pharmaceuticals sells about $5.6 million of common stock in PIPE". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/telomir-pharmaceuticals-sells-about-5-6-million-common-stock-pipe/). What is the ticker symbol of Telomir Pharmaceuticals? Telomir Pharmaceuticals, Inc. trades under the ticker TELO on NASDAQ. Where is Telomir Pharmaceuticals listed? Telomir Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Telomir Pharmaceuticals? The SEC Central Index Key (CIK) for Telomir Pharmaceuticals, Inc. is 1971532. Its filings are on SEC EDGAR. How many shares does Telomir Pharmaceuticals have outstanding? 68,774,956 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Telomir Pharmaceuticals listed under? Our directory records Telomir Pharmaceuticals, Inc. under United States. What does Telomir Pharmaceuticals do? Our directory classifies Telomir Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Telomir Pharmaceuticals? The ISIN recorded for Telomir Pharmaceuticals, Inc. is US87975F1049. Does aibio.space cover Telomir Pharmaceuticals? aibio.space lists Telomir Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Telomir Pharmaceuticals incorporated? SEC records list its state or country of incorporation as FL. Is Telomir Pharmaceuticals profitable? Telomir Pharmaceuticals, Inc. reported a net loss of $10.4 million for the fiscal year ended Dec 31, 2025, and used $3.7 million of cash in operations, per its annual report to the SEC. How much does Telomir Pharmaceuticals spend on research and development? $2.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Telomir Pharmaceuticals have? $754,323 in cash at Jun 30, 2025, per its 10-Q. What is the latest Telomir Pharmaceuticals (TELO) stock news? Our latest story on Telomir Pharmaceuticals, dated Oct 6, 2026: "Telomir Pharmaceuticals sells about $5.6 million of common stock in PIPE". Telomir sold 4,843,300 shares at $1.16 each, a 5% discount to its 10-day VWAP, in a PIPE with no warrants. Alexander Capital, L.P. was placement agent, and John Paul DeJoria put in an additional $1.0 million. [Source](https://aibio.space/news/telomir-pharmaceuticals-sells-about-5-6-million-common-stock-pipe/). How long will Telomir Pharmaceuticals's cash last? From our story of May 21, 2025: It says the company's financial condition raises substantial doubt about its ability to continue as a going concern, and the auditor's report carries an explanatory paragraph to that effect. [Source](https://aibio.space/news/telomir-pharmaceuticals-raises-3-million-private-placement-largest/). ## Investor discussion: Telomir Pharmaceuticals Members talk about Telomir Pharmaceuticals (TELO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Telomir Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315226045860/ex99-1.htm) 2. 2026-04-24 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/form8-k.htm) 3. 2026-03-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315226013872/form8-k.htm) 4. 2026-03-17 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315226010625/form10-k.htm) 5. 2026-01-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315226001170/form8-k.htm) 6. 2025-11-20 Mergers Filed documents for a merger or acquisition. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315225024463/formprem14a.htm) 7. 2025-05-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1971532/000164117225011868/form8-k.htm) 8. 2025-02-14 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315225006943/forms-3.htm) 9. 2025-02-04 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315225004872/form10-k.htm) 10. 2024-12-20 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315224051090/form8-k.htm) 11. 2024-12-11 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1971532/000149315224049630/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TELO on TradingView](https://www.tradingview.com/symbols/NASDAQ-TELO/). ## SEC filings and registration - **SEC name**: Telomir Pharmaceuticals, Inc. - **CIK**: 1971532 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TELO (Nasdaq) - **State or country of incorporation**: FL - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 100 SE 2ND ST, MIAMI, FL, 33131 - **Phone**: 786-396-6723 - **Shares outstanding**: 68,774,956 as of 2026-08-12 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1971532/000149315226045860/form8-k.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1971532/000149315226043053/form8-k.htm) filed 2026-09-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1971532/000149315226042926/form8-k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1971532/000149315226042483/form8-k.htm) filed 2026-09-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1971532/000149315226037854/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1971532/000149315226036742/form8-k.htm) filed 2026-08-10 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1971532/000149315226035026/formdef14a.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1971532/000149315226028614/form8-k.htm) filed 2026-06-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001971532), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Telomir Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TELO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Telomir Pharmaceuticals, Inc. - **Ticker**: TELO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US87975F1049 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TELO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/telomir-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Telomir Pharmaceuticals (TELO) news: offering", 2026-10-31, https://aibio.space/companies/telomir-pharmaceuticals/